Brief: Shandong Boan Biotechnology Completes Patient Enrollment in China For PhaseIII Study Of Ba5101
15/05/2023 13:51
May 15 (Reuters) - Shandong Boan Biotechnology Co Ltd
6955.HK :
* PATIENT ENROLLMENT COMPLETED FOR PHASE III- CLINICAL STUDY
OF
BA5101 IN CHINA
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil